module 4: antigens & immunogens

0.0(0)
studied byStudied by 0 people
0.0(0)
full-widthCall with Kai
GameKnowt Play
New
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/37

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

38 Terms

1
New cards

antigens

bind to components of the immune response but do not elicit an immune response (ex: haptens)

2
New cards

antigenicity

the ability to combine specifically with the products of the humoral and/or cell-mediated responses

3
New cards

immunogens

evoke an immune response & bind to components of the immune response

4
New cards

haptens 

small molecules that display antigenicity but not immunogenicity. “all immunogens are antigens, but not all antigens are immunogens”. may bind antibodies, but cannot activate B cells on their own. when covalently attached to a carrier molecule (macromolecule), an immune response can be elicited.

5
New cards

epitope/antigenic determinant

antigenic site which binds to an antibody OR gives rise to the MHC-binding peptide recognized by a T-cell receptor. approximately 6 amino acids or 5-7 monosaccharides in length.

<p>antigenic site which binds to an antibody OR gives rise to the MHC-binding peptide recognized by a T-cell receptor. approximately 6 amino acids or 5-7 monosaccharides in length.</p>
6
New cards

structural features of variable region

most sequence differences in antibodies are confined to 3 short stretches in the variable (V) region of the heavy & light chains. the chains are called complementary determining region (CDR) or hypervariable region. all CDRs or hypervariable regions contribute to epitope binding. contains paratopes

<p>most sequence differences in antibodies are confined to 3 short stretches in the variable (V) region of the heavy &amp; light chains. the chains are called complementary determining region (CDR) or hypervariable region. all CDRs or hypervariable regions contribute to epitope binding. contains paratopes</p>
7
New cards

paratope

the antibody combining site

<p>the antibody combining site</p>
8
New cards

B cell epitopes

determined by the nature of antigen binding site on the antibody molecule displayed by these. can contain sequential or non-sequential (conformational) epitopes. nature of antigens are proteins, polysaccharides, or lipids.

9
New cards

linear (sequential) epitope

a continuous sequence of amino acids recognized by an antibody

<p>a continuous sequence of amino acids recognized by an antibody</p>
10
New cards

conformational (discontinuous) epitope 

amino acids that are distant in protein’s primary sequence, but brought together in 3D structure through folding

<p>amino acids that are distant in protein’s primary sequence, but brought together in 3D structure through folding</p>
11
New cards

T cell epitopes

do not recognize soluble antigens. antigens must be processed by antigen presenting cells. antigen peptides recognized by these form tri-molecular complexes with a T cell receptor and an MHC molecule presenting a peptide. can be linear or continuous. often internal

<p>do not recognize soluble antigens. antigens must be processed by antigen presenting cells. antigen peptides recognized by these form tri-molecular complexes with a T cell receptor and an MHC molecule presenting a peptide. can be linear or continuous. often internal</p>
12
New cards

antigen recognition by B cells

involves binary complex of membrane Ig & Ag. binds with soluble antigen. no MHC molecules. antigens are protein, polysaccharide, lipid. epitope is accessible, hydrophilic, mobile, peptide containing sequential or non-sequential aa

13
New cards

antigen recognition by T cells

involves ternary complex of T cell receptor, Ag, MHC molecule. does not bind to soluble antigen. MHC required to display processed antigen. antigens are mostly proteins with some lipids & glycolipids. epitope is internal linear peptide produced by processing of antigen & bound to MHC molecules.

14
New cards

what makes a substance immunogenic?

“foreign-ness”, high MW, chemical composition & complexity, degradability. additional requirements (host dependent): genetic composition, dose & route of administration

15
New cards

“foreign-ness”

something that is not naturally occurring. body cannot recognize it as it’s own.

<p>something that is not naturally occurring. body cannot recognize it as it’s own. </p>
16
New cards

large size (high MW)

compounds that weigh less than 100 Da are not immunogenic (penicillin, progesterone, aspirin). higher than 10,000 Da are immunogenic only if they have chemical complexity

17
New cards

chemical composition & complexity

compounds with high MW & no chemical complexity, such as homopolymeric compounds, are not immunogenic (ex: poly-lysine)

<p>compounds with high MW &amp; no chemical complexity, such as homopolymeric compounds, are not immunogenic (ex: poly-lysine)</p>
18
New cards

degradability

to activate T cells, antigens must be processed by APCs. APC degrades the antigen into small fragments. small fragments of the immunogen (antigenic epitope) are noncovalently bound to MHC & expressed on the surface of the APC. non-biodegradable substances are not immunogenic: silicone implants, stents, hip implants

<p>to activate T cells, antigens must be processed by APCs. APC degrades the antigen into small fragments. small fragments of the immunogen (antigenic epitope) are noncovalently bound to MHC &amp; expressed on the surface of the APC. non-biodegradable substances are not immunogenic: silicone implants, stents, hip implants</p>
19
New cards

carrier molecule

immunogenic molecule that is recognized by T cells. conjugation of a carrier to nonimmunogenic hapten makes the hapten immunogenic. ex: bovine serum albumin, keyhole limpet hemocyanin

20
New cards

hapten-carrier conjugate 3 types of antibodies

  1. against hapten

  2. against carrier

  3. against the new epitope formed by combined parts of hapten & carrier

<ol><li><p>against hapten</p></li><li><p>against carrier</p></li><li><p>against the new epitope formed by combined parts of hapten &amp; carrier </p></li></ol><p></p>
21
New cards
<p>penicillin</p>

penicillin

a hapten that sometimes elicits antibody production causing type II hypersensitivity reactions. acts as a substrate for bacterial transpeptidase, thereby inactivating the enzyme permanently: prevent cell wall synthesis. sometimes the same mechanism couples this to red blood cells, causing the formation of a hapten-carrier moiety, which then leads to production of antibodies

22
New cards

primary structure

at amino acid sequence level

<p>at amino acid sequence level</p>
23
New cards
<p>secondary structure</p>

secondary structure

backbone of the polypeptide chain

24
New cards

tertiary structure

3 dimensional molecule

<p>3 dimensional molecule</p>
25
New cards

quaternary structure

association of 2 or more polypeptides

<p>association of 2 or more polypeptides</p>
26
New cards

genetic composition

factor from the host that can influence immunogenicity. controlled by genes mapped within the major histocompatibility antigen (MHC). ex: 85% of people with HLA-A9 produce high [antibody] for tetanus toxoid.

27
New cards

route, dose, & timing of administration

factor from the host that can influence immunogenicity. subcutaneous, intravenous, gastrointestinal injections. type of immunogen processing: T-cell dependent or T-cell independent. amount of immunogens can lead to immune response or no response (tolerance)

28
New cards

primary response

immune response to first immunogen exposure. naive B cells are stimulated by immunogen & differentiate into Ab-secreting cells that produce Abs specific for the eliciting Ag. long lived memory cells are also produced during this response

29
New cards

secondary response

immune response to the second exposure of an immunogen after the first response has leveled off or has totally subsided. when the same immunogen is encountered by memory B cells, rapid proliferation & differentiation occurs and production of greater quantities of specific Abs than in the first response

30
New cards

conformation of the target antigen (epitope) & antibody sites

complementary. Ab forms multiple non-covalent bonds with Ag. recognition of Ag by Ab involves non-covalent reversible binding. for epitope to bind to Ab combining site, there must be suitable atomic groupings on opposing parts of the Ag & Ab. the shape of the combining site must fit the epitope

31
New cards

the strength of a non-covalent bond is critically dependent on…

the distance between the interacting groups. the interacting groups must be in close proximity (in molecular terms) before the forces become significant

<p>the distance between the interacting groups. the interacting groups must be in close proximity (in molecular terms) before the forces become significant</p>
32
New cards

affinity

strength of the binding between an epitope & single combining site of an antibody. the sum of the attractive & repulsive forces between them. represented as a dissociation constant (Kd). to calculate this, use either equilibrium dialysis or surface plasma resonance

<p>strength of the binding between an epitope &amp; single combining site of an antibody. the sum of the attractive &amp; repulsive forces between them. represented as a dissociation constant (K<sub>d</sub>). to calculate this, use either equilibrium dialysis or surface plasma resonance</p>
33
New cards

small Kd

indicates high affinity between Ag & Ab because low concentrations of Ag are required to bind to the Ab site. typical Kd for antibodies produced in the immune system vary from 10-7M to 10-11M

34
New cards

avidity

the relative tendency (indicated by strength of binding) for multiple antibodies & multivalent Ags to combine. the cumulative binding strength of all antibody-epitope pairs. high for IgG as it is bivalent (2 binding sites). very high for IgM as it is polyvalent (10 binding sites)

<p>the relative tendency (indicated by strength of binding) for multiple antibodies &amp; multivalent Ags to combine. the cumulative binding strength of all antibody-epitope pairs. high for IgG as it is bivalent (2 binding sites). very high for IgM as it is polyvalent (10 binding sites)</p>
35
New cards

heterophile antibody

an antibody elicited by one antigen can cross-react with a second unrelated antigen. cross-reactivity occurs because the epitopes between these antigens are identical or similar

36
New cards

examples of cross-reactivity

  1. antibody against Group A Streptococcus also reacts with human myocardium & may lead to rheumatic fever.

  2. one antibody elicited against Epstein Barr virus reacts with sheep RBCs (SRBC). by measuring the heterophiles antibody against SRBC clinically, indirect evidence of recent EBV infection can be determined

  3. vaccinia virus which causes cowpox expresses cross-reacting epitopes with variola virus (causative agent of smallpox)

37
New cards

ABO blood group

microbial antigens present in common intestinal bacteria elicit antibody that cross-reacts with ABO blood group antigens. microbial antigens induce the formation of antibodies in individuals lacking the similar blood group antigens on their blood cells. for A type blood, microbial antigens can induce the formation of anti-B antibodies but not anti-A. during the developmental stage, the B cells that elicit antibodies against self-antigens (self-epitopes) are eliminated. anti-B antibodies are produced by cross-reacting microbial antigens present in common intestinal bacteria

38
New cards

adjuvants

agents that potentiate immune responses, but are not immunogens. increase the biological half-life of vaccines (forms complex & allows for slow release of immunogens). induce production of local inflammatory responses (recruits phagocytic cells). improve antigen delivery & processing by APC. ex: water in oil emulsion (freund’s incomplete)